2013
DOI: 10.1007/174_2012_782
|View full text |Cite
|
Sign up to set email alerts
|

Therapeutic Radionuclides: Production, Physical Characteristics, and Applications

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
34
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 26 publications
(34 citation statements)
references
References 84 publications
0
34
0
Order By: Relevance
“…In this field, a working compromise is always sought among the standard chemical separation methods; however, they are not easily applicable since the conditions are mostly of non-equilibrium, and safe procedures for the treatment of radioactive materials impose certain safety boundaries on separation methods [60]. Indeed, the reactor- or accelerator-produced radionuclide processing has to take place in a shielded and controlled environment, such as a radiochemistry hood or hot cell inside laboratories that are authorized to perform the detention and handling of radioactive tracers and waste [61]. Moreover, if the product of interest is intended for human use, Pharmacopoeia and similar regulatory bodies impose specific product quality requirements for injection, such as sterility, apirogenicity, specific activity, as well as chemical, radiochemical and radionuclidic purity.…”
Section: Use Of Lle For Radioisotopes Productionmentioning
confidence: 99%
See 1 more Smart Citation
“…In this field, a working compromise is always sought among the standard chemical separation methods; however, they are not easily applicable since the conditions are mostly of non-equilibrium, and safe procedures for the treatment of radioactive materials impose certain safety boundaries on separation methods [60]. Indeed, the reactor- or accelerator-produced radionuclide processing has to take place in a shielded and controlled environment, such as a radiochemistry hood or hot cell inside laboratories that are authorized to perform the detention and handling of radioactive tracers and waste [61]. Moreover, if the product of interest is intended for human use, Pharmacopoeia and similar regulatory bodies impose specific product quality requirements for injection, such as sterility, apirogenicity, specific activity, as well as chemical, radiochemical and radionuclidic purity.…”
Section: Use Of Lle For Radioisotopes Productionmentioning
confidence: 99%
“…It provides a high selectivity even when dealing with very low concentrations, as partition conditions can be easily varied to obtain radioisotope yields relatively free from chemical and radionuclidic impurities. LLE can be performed rapidly (a particularly vital characteristic when isolating isotopes with shorter half-lives), and is relatively simple to automate [61,63]. Typically, LLE is followed by evaporation of the extracting solvent, back extraction in aqueous phase or SPE/chromatography to purify the radionuclide from the organic phase and dissolved into a solution phase appropriate for successive radiolabelling or injection.…”
Section: Use Of Lle For Radioisotopes Productionmentioning
confidence: 99%
“…The calculated (α, n) and (α, 2n) (α, 3n) reaction cross sections for 209 Bi(α, n) 212 [1]. The obtained results were then compared with the experimental data existing in the EXFOR databases [24,25]. The values of the cross section were expressed in (10 −3 barns), while that of energies in (MeV) [15].…”
Section: Computer Code Complet Calculationsmentioning
confidence: 99%
“…When 209 Bi is bombarded by alpha particle, it can produce 211 At with two neutrons [8,25]. Based on the EXFOR database and computer code COMPLET, the results for (α, 2n) reaction channel are tabulated as in table 2 [18,19].…”
Section: Bi (α 2n) 211 At Nuclear Reactionmentioning
confidence: 99%
“…Theranostic applications in molecular imaging and therapy involve the use of a radionuclide or radionuclide pairs with nuclear, physical, and biological characteristics that allow tailored imaging and therapy in the same patient [1]. This personalized approach to nuclear medicine offers the possibility of matching the properties of different theranostic radionuclides with a targeting vector for distinct tumor types.…”
Section: Introductionmentioning
confidence: 99%